PMHNP Clinical Guide
Many practitioners are trained on standard induction protocols assuming short-acting opioid use — but the current crisis is dominated by illicit fentanyl, which has a longer tissue half-life and creates higher risk of precipitated withdrawal during standard induction.
High receptor binding affinity displaces full agonists
Move from full agonist dependence to stabilization
Avoids withdrawal window entirely for fentanyl
16-24 mg/day — underdosing is most common error
Buprenorphine's ceiling effect makes it safer than full agonists, but its high affinity means timing is everything. Give too early = precipitated withdrawal. Give too late = unnecessary suffering.
Current opioid type determines induction method: short-acting opioids → standard induction; fentanyl → low-dose/microdose preferred
| Factor | Standard Induction | Low-Dose (Microdose) | Home Induction |
|---|---|---|---|
| Best For | Short-acting opioid users willing to enter withdrawal | Fentanyl users; patients unable/unwilling to stop first | Stable, motivated patients with prior experience |
| Requires Withdrawal? | Yes — COWS ≥8-12 | No — can overlap use | Yes — moderate withdrawal |
| Setting | Office (preferred) or home | Office or home with close follow-up | Home with phone/telehealth support |
| Duration | 1-3 days | 3-7 days | 1-3 days |
| Precipitated Withdrawal Risk | Moderate (high with fentanyl) | Very low | Moderate |
| Day | Dosing Protocol | Key Actions |
|---|---|---|
| Day 1 | 2-4 mg SL initial dose | Confirm COWS ≥8-12; reassess at 1-2 hours; may give additional 2-4 mg (max 8 mg) |
| Day 2 | 8-16 mg SL | Assess symptom control; single dose or split BID |
| Day 3-7 | Titrate to 16-24 mg/day | Most stabilize at 16 mg; many need 24 mg based on cravings |
| Score | Severity | Action |
|---|---|---|
| 0-4 | No withdrawal | Do NOT induce — risk of precipitated withdrawal |
| 5-7 | Mild | Consider waiting for higher score |
| 8-12 | Moderate | Safe to induce — ideal range |
| 13-24 | Moderate-Severe | Induce and provide symptom management |
| 25+ | Severe | Induce immediately; consider ED if medically unstable |
When in doubt, wait. Precipitated withdrawal is intensely dysphoric and may damage therapeutic alliance. Better to have patient wait 2-4 more hours than to induce prematurely.
Patient does NOT need to stop opioid use first. Buprenorphine is introduced at sub-threshold doses and gradually increased while the full agonist is tapered.
| Day | Buprenorphine Dose | Notes |
|---|---|---|
| 1 | 0.5 mg SL | Patient continues usual opioid use |
| 2 | 0.5 mg SL BID (1 mg total) | — |
| 3 | 1 mg SL BID (2 mg total) | Begin reducing other opioid use |
| 4 | 2 mg SL BID (4 mg total) | — |
| 5 | 4 mg SL BID (8 mg total) | Discontinue other opioids |
| 6 | 8 mg SL BID (16 mg total) | Full transition complete |
| 7+ | Titrate to 16-24 mg/day | Maintenance dosing |
16-24 mg/day
Once daily preferred
BID if evening cravings
UDS weekly x4, then monthly
The most common maintenance error is prescribing 2-8 mg/day. This is subtherapeutic for most patients. Evidence supports that higher doses (16-24 mg) improve retention. Don't be afraid to push to effective dosing.
The #1 induction complication. Occurs when buprenorphine displaces full agonists before patient is sufficiently withdrawn. Prevent with proper COWS scoring and timing.
Tissue depot effects mean COWS may underestimate residual fentanyl binding. When uncertain, use low-dose induction.
2-8 mg/day is subtherapeutic for most patients. Push to 16-24 mg/day based on cravings and withdrawal suppression.
Increases overdose risk but is NOT an absolute contraindication. Consider dose reduction or supervised dispensing.
Telehealth follow-up dramatically improves retention, especially in rural and underserved areas. Don't let administrative barriers delay treatment initiation — "start where the patient is."
| Population | Consideration | Recommendation |
|---|---|---|
| Pregnancy | Buprenorphine is safe; naloxone component is the concern | Prefer buprenorphine monoproduct (Subutex) |
| Hepatic Disease | Hepatotoxicity rare at therapeutic doses | Monitor LFTs; avoid if severe hepatic impairment |
| QTc Risk | Not a significant concern with buprenorphine | Unlike methadone, routine ECG not needed |
| Diversion Risk | Lower than perceived | Most diversion is "self-treatment"; harm reduction approach |
Film formulation has more consistent bioavailability than tablets. Prefer Suboxone film or authorized generics for predictable dosing.
For patients who struggle with sublingual administration, buccal placement is an acceptable alternative with similar absorption.
Remote induction and follow-up visits are effective and improve retention. Don't require in-person visits if barriers exist.
Don't let administrative barriers delay treatment. Document treatment agreement but prioritize engagement over paperwork.
PCSS training modules available at pcssNOW.org | SAMHSA practitioner training at samhsa.gov